The following is a summary of the SIGA Technologies, Inc. (SIGA) Q1 2024 Earnings Call Transcript:

Financial Performance:

• SIGA reported a rise in product revenues to $24 million in Q1 2024, with a pre-tax operating income of $11 million.

• The leading revenue drivers were sales of oral TPOXX, including $60 million to the U.S. government and $8 million to 8 international customers.

• The company achieved a turnaround in net income, reporting $13 million in Q1 2024 as opposed to a net loss of $1 million in Q1 2023.

• SIGA ended Q1 2024 with a robust cash balance of around $144 million and no debt.

Business Progress:

• SIGA is driving long-term success through strategic decision making, key operating initiatives, and disciplined capital management.

• Through an agreement amendment with Meridian Medical Technologies, SIGA now controls the marketing and promotion of oral TPOXX from June 1, 2024.

• The company welcomed a new Vice President for International Markets.

• TPOXX's global presence has been broadened by expanding its approvals to new indications and formats, especially through the PEP and mpox programs.

• A new drug application for TPOXX has been filed in Japan for treating various orthopoxvirus-related conditions.

• SIGA predicts a strong financial performance throughout 2024, including an impending order for oral TPOXX under the current BARDA contract.

• The company is actively involved in the global response against the mpox outbreak in the DRC and the possible spread of other orthopoxviruses.

More details: SIGA Technologies IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.